Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars PromactaⓇ - Thrombopoetin receptor agonist PromactaⓇ - Thrombopoetin receptor agonist NCT03025698 (CETB115E2201) Refractory or relapsed severe aplastic anemia Indication Phase Phase 2 Patients 51 Primary Outcome Measures Arms Intervention Target Patients Read-out NCT03988608 (CETB115E2202) Indication Phase Refractory or relapsed severe aplastic anemia Phase 2 Patients 20 PK of eltrombopag at steady state in pediatric patients with SAA Primary Outcome Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Milestone(s) Final CSR: 2025 Hematologic response rate rate up to 26 weeks of treatment Measures Arms Eltrombopag 25 mg film-coated tablets Intervention Target Patients Chinese patients with refractory or relapsed severe aplastic anemia Primary CSR: 2021 Read-out Milestone(s) Interim CSR: 2022 Final CSR:2025 Publication TBD Publication TBD 58 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation